Oral antihyperglycaemics in type 2 diabetes reviewed

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1322, 2002-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Type 2 Diabetes and Oral Antihyperglycemic Drugs

Current Medicinal Chemistry, Vol. 15, Iss. 1, 2008-01 ,pp. : 61-74

Bentham Science Publishers

Access to resources Recommend Favorite

Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus

By Krentz Andrew J.

Drugs, Vol. 65, Iss. 3, 2005-01 ,pp. : 385-411

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

By Ward Alexandra O’Brien Judith A Salas Maribel

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes

Current Bioactive Compounds, Vol. 4, Iss. 2, 2008-01 ,pp. : 68-85

Bentham Science Publishers

Access to resources Recommend Favorite

The oral antihyperglycaemic agent nateglinide [`Starlix'] has been approved in Switzerland for the treatment of type 2 diabetes mellitus.

Inpharma, Vol. 1, Iss. 1259, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite